• Objectives: To characterize patient sample, treatment patterns, and provide 1-year costs of an ongoing observational study of pediatric Attention Deficit/Hyperactivity Disorder (ADHD) patients in Europe.
• Methods: AUTOR is a European observational study investigating factors associated with ADHD severity changes across a 2-year follow-up period in patients aged 6-17 that are stable responders on their first pharmacotherapy. At baseline, patients must have taken their ADHD medication for 3-8 months and have a Clinical Global Impression Severity score ≤3 and Improvement score ≤2 compared to treatment initiation. Data were collected at months 0, 3, 6, 9, 12, 18, and 24. UK unit costs of health & social care (PSSRU 2011) were used for analysis. • Conclusions: The AUTOR sample differs from clinical trials in its higher prevalence of comorbid conditions. There is substantial 1-year mean cost associated with pediatric ADHD, even for stable responders on their pharmacotherapy. Notably, only one quarter of the cost of ADHD is due to medication.
• Attention Deficit/Hyperactivity Disorder (ADHD) is one of the most common chronic conditions of childhood 1 .
• ADHD is characterized by inattention, impulsivity and hyperactivity, including problems with schools and authorities 2 , and is often associated with other psychiatric comorbidities, such as oppositional defiant disorder, anxiety or mood disorders 3 .
• Adverse consequences of ADHD persist through adolescence into adulthood, including academic impairment, social dysfunction, and poor self-esteem 4 .
• The economic burden of ADHD is high for affected individuals, their families and society 5, 6 . • A recently published study of 5-year longitudinal follow-up data on adolescents in the UK who had been diagnosed as children found the mean annual medical, educational, and social services cost inflated to 2011 to be £5655.87, 95% CI (£4546.92, £6877.10) 7, 8 .
• Current treatment guidelines for ADHD suggest a range of pharmacological, social, psychological and behavioral interventions 9 .
• This European observational study ("AUTOR") is still ongoing. Primary objective of the study is to describe factors associated with an increase in ADHD symptom severity during a 2-year follow-up period in pediatric patients that are responders and stable on their first pharmacotherapy.
• Objective of this presentation is to characterize the patient sample and provide 1-year costs.
METHODS
• Eligibility criteria: -Patients aged 6-17 years and diagnosed with ADHD -Stable responders on their first pharmacotherapy: 8ADHD medication for 3-8 months prior to entry 8Clinical Global Impression-ADHD-Severity Scale (CGI-ADHD-S) score ≤3 8Clinical Global Impression-ADHD-Improvement Scale (CGI-ADHD-I) score ≤2 compared to treatment initiation • Data have been collected at naturally occurring visits when the visit coincided with one of following observation windows: 0, 3, 6, 9, 12, 18 and 24 months, +/-6 weeks (from baseline).
• Symptom severity is measured with the CGI-ADHD-S and the ADHD rating scale-IV-Parent Version-Investigator completed (ADHD-RS).
• Severity of comorbid disorders is assessed based on clinical judgment by investigator-completed single item questions using the CGI-S.
• Information on visits to accident and emergency facilities and medical service providers, as well as contacts with social services and law enforcement is captured by resource utilization and cost questions adapted from the Resource Utilisation Questionnaire (RUQ).
Statistical Methods
• All patients who provided consent to release information and who fulfilled the study entry criteria (eligible patients) were included in the analysis.
• The interim analysis was conducted once all eligible patients had completed their 1-year visit or discontinued.
• Descriptive statistics are used.
• Definition of direct/indirect costs: -Direct costs: pharmacotherapy treatment, non-pharmacotherapy treatment, medical contacts -Indirect costs: property damage, absenteeism, loss of leisure time, and visits to health center or hospital due to an accident • Costs were calculated by multiplying the usage by the unit cost or by using the actual cost when it was collected directly on the CRF.
• For patients who discontinued early, costs are only for the period they were followed in the study.
• UK unit costs of health & social care (PSSRU 2011) were used for analysis, and IMS PADDS Quarterly MIDAS database mean daily drug price served as pharmacotherapy unit costs. Race, Caucasian, n (%) 695 (98.9)
Gender, male, n (%) 573 (81. The authors want to thank all patients and investigators that have been involved in this study.
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• The proportion of patients receiving atomoxetine (56%) was much higher than one would expect from clinical practice.
• Only 1% of patients received combination therapy, which might be an underestimation of the prevalence of prescribing combination therapy in clinical practice.
• For those patients who were lost to follow-up or dropped out of the study, analyses included all data up to the point of their last data collection. Thus, costs for some patients are underestimated.
• There is inherent variability in access to health care by country that introduces a bias in estimating true ADHD total 1-year costs. Future work will include analysis of resource units by country. • Country differences will be investigated as next step.
Limitations

CONCLUSIONS
• The AUTOR sample differs from mainstay clinical trial populations in its higher prevalence of comorbid conditions. -This is perhaps not surprising given that many comorbidities are exclusion criteria in clinical trials and thus, reiterate the value of observational studies which more accurately capture real life everyday clinical realities.
• Relatively few patients switched, discontinued, or changed the dose of the medication to which they were responding.
-The lack of switching and discontinuation is likely due to the population studied, patients who were responding to their first ADHD pharmacotherapy.
• There is substantial 1-year mean cost associated with pediatric ADHD, even for stable responders to pharmacotherapy.
-ADHD is associated with substantial indirect costs.
-Only one quarter of the costs of ADHD is due to medication. • The estimated total cost of treating ADHD responders in AUTOR is at the lower end of what was found in literature for the published total cost of treating pediatric emotional and behavioral disturbances or antisocial behavior, £5579.68 to £48945.52; converted to 2011 values 6,8,10 .
• AUTOR extends the existing literature 6,7 on the cost of ADHD by providing figures associated with actual resource utilization, including indirect costs, in seven European countries.
• The estimated annual direct and treatment cost of treating ADHD responders from AUTOR is quite similar to the published annual direct and treatment costs of treating adolescents in the UK derived from resource utilization data collected in the CLASS study, converted to 2011 values 7, 8 .
Non-drug Concomitant Therapy at Baseline
A total of 251 patients (35.7%) have been receiving at least one session of non-drug concomitant therapy*:
• 
